Articles
The people to deliver – every day is valuable.
We are people on a mission. Our aim is to reduce suffering and help people around the world gain a better quality of life. We are dedicated to being one of the top research sites in Asia-Pacific.
“They have impressively fast start up times due to efficient yet robust ethics and regulatory systems.”
US Biotech
Optimal Clinical Trials is a private, independently owned, clinical research site in central Auckland – New Zealand’s largest city with a population of over 1.4 million people. Optimal has grown rapidly and is a Deloitte Fast 50 company and winner of multiple awards.
Provide Data
Report Results
Commission trial
Enroll & support
Participants
Optimal
CROs
& Sponsors
We specialise in conducting commercial phase 1b to 3 trials across a wide range of therapeutic areas, our team of expert investigators, doctors and research professionals make this possible.
We regularly work with the world’s largest pharmaceutical companies, Contract Research Organisations and many US biotechs. We are recognised for our speed, quality and responsiveness to clients’ needs.
We specialise in a wide range of therapeutic areas
Analgesia
CRPS, Acute Pain, Chronic Pain
Vaccines
Vaccines, Antivirals
Cardiovascular
CAD, Hypertension, Hyperlipidaemia
CNS/Neurology
Autism spectrum disorder, ADHD, Multiple Sclerosis, Parkinson’s Disease
Dermatology
Acne, Atopic Dermatitis, Psoriasis
ENT
Chronic Sinusitis
Diabetes & Endocrinology
Diabetes (type 1 and 2), obesity, HRT, osteoporosis, paediatric metabolic
Gastroenterology
Coeliac disease
Infectious diseases
Influenza, RSV
Women's Health
Women’s health, Menopause
Orthopaedics
Respiratory
Asthma, COPD, Chronic Cough
Rheumatology
Rheumatoid arthritis, giant cell arteritis
Plant & Natural
Cannabidiol, Honey
Paediatrics
Vaccine, Autism Spectrum Disorder
Psychiatry
Depression
Geriatric
Family medicine
General practice
Healty Volunteers
Rare / Orphan Diseases
Immunology & Allergy
Who We've Worked With In The Past
Sponsors
CROs
Latest Key Stats
First Patient In
- Global First patient in Neurology phase 1b study (Mar 19)
- Global First patient in Immunology phase 3 study (April 19)
- Global First patient in Paediatric phase 1b study (April 19)
- New Zealand First patient in Dermatology phase 2a study (April 19)
Highest recruiting site
- Global Immunology phase 3 study (May 19)
- Australasia Vaccine phase 3 study (April 19)
- Australasia Metabolic phase 2a study (Jul 18)